Treatment of type III hyperlipoproteinemia

被引：11
作者：
Guyton, JR
机构：
[1] Duke Univ, Med Ctr, Dept Med,Sarah W Stedman Nutr Ctr, Div Metab Endocrinol & Nutr, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Sarah W Stedman Nutr Ctr, Dept Pathol, Durham, NC 27710 USA
来源：
AMERICAN HEART JOURNAL | 1999年 / 138卷 / 01期
关键词：
D O I：
10.1016/S0002-8703(99)70239-5
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：17 / 18
页数：2
相关论文
共 5 条
[1]   Comparison of the hypolipidemic effect of gemfibrozil versus simvastatin in patients with type III hyperlipoproteinemia [J].
Civeira, F ;
Cenarro, A ;
Ferrando, J ;
Puzo, J ;
Garcia-Otín, AL ;
Mozas, P ;
Pocoví, M .
AMERICAN HEART JOURNAL, 1999, 138 (01) :156-162
[2]   Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness [J].
Hodis, HN ;
Mack, WJ ;
Dunn, M ;
Liu, CR ;
Selzer, RH ;
Krauss, RM .
CIRCULATION, 1997, 95 (08) :2022-2026
[3]   THE HYPOLIPIDEMIC EFFECTS OF LOVASTATIN AND CLOFIBRATE ALONE AND IN COMBINATION IN PATIENTS WITH TYPE-III HYPERLIPOPROTEINEMIA [J].
ILLINGWORTH, DR ;
OMALLEY, JP .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1990, 39 (04) :403-409
[4]   APOLIPOPROTEIN-E - CHOLESTEROL TRANSPORT PROTEIN WITH EXPANDING ROLE IN CELL BIOLOGY [J].
MAHLEY, RW .
SCIENCE, 1988, 240 (4852) :622-630
[5]  
Mahley RW, 1995, METABOLIC MOL BASES, P1953
1